Axis-Shield

Under the terms of the agreement, the financial details of which were not disclosed, Bio-Rad will have the right to develop the heparin binding protein marker for use on its proprietary laboratory instruments worldwide.

Under the terms of the agreement, Bio-Rad will have the right to develop the HBP marker for use on its proprietary laboratory instruments globally. Additional terms of the deal were not disclosed.

With FDA clearance, the test, which had been available outside the US, will now become available in the US.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.